Cerevel Therapeutics - CERE Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $41.78
  • Forecasted Upside: 43.76 %
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$29.06
▲ +0.8 (2.83%)

This chart shows the closing price for CERE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cerevel Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CERE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CERE

Analyst Price Target is $41.78
▲ +43.76% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Cerevel Therapeutics in the last 3 months. The average price target is $41.78, with a high forecast of $50.00 and a low forecast of $28.00. The average price target represents a 43.76% upside from the last price of $29.06.

This chart shows the closing price for CERE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 10 polled investment analysts is to buy stock in Cerevel Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/11/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/10/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/8/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/6/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/6/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/5/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/3/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/3/2022

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/29/2022Cantor FitzgeraldInitiated CoverageOverweight$41.00Low
9/26/2022Wells Fargo & CompanyInitiated CoverageOverweight$38.00Low
9/21/2022The Goldman Sachs GroupBoost TargetNeutral$24.00 ➝ $28.00Low
9/12/2022Evercore ISIInitiated CoverageOutperformLow
8/23/2022MizuhoBoost TargetNeutral$27.00 ➝ $32.00Low
8/22/2022Morgan StanleyBoost TargetOverweight$39.00 ➝ $50.00Low
8/3/2022MizuhoLower TargetNeutral$30.00 ➝ $27.00N/A
7/6/2022MizuhoInitiated CoverageNeutral$30.00N/A
5/24/2022The Goldman Sachs GroupLower TargetNeutral$28.00 ➝ $20.00Medium
2/15/2022The Goldman Sachs GroupInitiated CoverageNeutral$27.00High
1/5/2022JPMorgan Chase & Co.Initiated CoverageOverweight$50.00Medium
12/16/2021HC WainwrightInitiated CoverageBuy$50.00High
11/10/2021Stifel NicolausBoost TargetBuy$33.00 ➝ $50.00High
10/8/2021Jefferies Financial GroupBoost TargetBuy$30.00 ➝ $37.00Low
9/7/2021Morgan StanleyBoost TargetOverweight$27.00 ➝ $39.00High
7/13/2021Stifel NicolausBoost TargetPositive ➝ Buy$21.00 ➝ $33.00Medium
6/18/2021Morgan StanleyInitiated CoverageOverweight$27.00High
12/10/2020The Goldman Sachs GroupInitiated CoverageBuy$24.00N/A
11/24/2020SidotiDowngradeHoldN/A
11/23/2020Jefferies Financial GroupInitiated CoverageBuy$18.00N/A
11/9/2020Stifel NicolausInitiated CoverageBuy$17.00N/A
(Data available from 10/4/2017 forward)

News Sentiment Rating

0.50 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/7/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/6/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/6/2022
  • 1 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/5/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/5/2022
  • 3 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/4/2022
  • 5 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/3/2022
  • 3 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/3/2022

Current Sentiment

  • 3 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Cerevel Therapeutics logo
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I clinical trial for the treatment of substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder; and CVL-047, selective PDE4 inhibitor for the treatment of major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and an LRRK2 inhibitor program to address disease progression in Parkinson's. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $29.06
Low: $27.93
High: $29.73

50 Day Range

MA: $30.38
Low: $25.50
High: $41.42

52 Week Range

Now: $29.06
Low: $19.86
High: $46.16

Volume

474,584 shs

Average Volume

594,436 shs

Market Capitalization

$4.32 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.81

Frequently Asked Questions

What sell-side analysts currently cover shares of Cerevel Therapeutics?

The following sell-side analysts have issued stock ratings on Cerevel Therapeutics in the last year: Cantor Fitzgerald, Evercore ISI, HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., Mizuho, Morgan Stanley, Stifel Nicolaus, The Goldman Sachs Group, Inc., and Wells Fargo & Company.
View the latest analyst ratings for CERE.

What is the current price target for Cerevel Therapeutics?

9 Wall Street analysts have set twelve-month price targets for Cerevel Therapeutics in the last year. Their average twelve-month price target is $41.78, suggesting a possible upside of 43.8%. JPMorgan Chase & Co. has the highest price target set, predicting CERE will reach $50.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $28.00 for Cerevel Therapeutics in the next year.
View the latest price targets for CERE.

What is the current consensus analyst rating for Cerevel Therapeutics?

Cerevel Therapeutics currently has 2 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CERE will outperform the market and that investors should add to their positions of Cerevel Therapeutics.
View the latest ratings for CERE.

What other companies compete with Cerevel Therapeutics?

How do I contact Cerevel Therapeutics' investor relations team?

Cerevel Therapeutics' physical mailing address is 1535 Rancho Conejo Blvd, THOUSAND OAKS, CA 91320-1440, United States. The biotechnology company's listed phone number is 844-304-2048 and its investor relations email address is [email protected] The official website for Cerevel Therapeutics is ceres.net. Learn More about contacing Cerevel Therapeutics investor relations.